On July 13, 2022, the Company announced a restructuring plan to prioritize its resources on its emerging pre-clinical and early clinical pipeline as well as its existing collaboration partnerships. The restructuring plan resulted in a reduction to its workforce of approximately 40%. Restructuring costs of $2.4 million and $5.1 million were recorded in general and administrative expense and research and development expense, respectively, in the third and fourth quarters of 2022. The restructuring was substantially complete as of December 31, 2022.

The following is a summary of accrued restructuring costs as of March 31, 2023 (in thousands):



	Severance and Benefits Costs			Contract Termination Cost			Stock Based Compensation		Total
Balance at December 31, 2022	$	1,512		$	164		$	-	$	1,676
Cash payment		(1,375	)		(50	)				(1,425	)
Change in estimates		(54	)		(114	)		-		(168	)
Balance at March 31, 2023	$	83		$	-		$	-	$	83